Home › Targets › BTK
BTK (3 companies · 17 programs)
Companies with an active program directed at BTK.
- bexobrutideg — Chronic Lymphocytic Leukemia Phase 2
- bexobrutideg — Small Lymphocytic Lymphoma Phase 2
- bexobrutideg — Waldenström's Macroglobulinemia Phase 1
- bexobrutideg — Follicular Lymphoma Phase 1
- bexobrutideg — Marginal Zone Lymphoma Phase 1
- zelebrudomide — Diffuse Large B-Cell Lymphoma Phase 1
- zelebrudomide — Mantle Cell Lymphoma Phase 1
- zelebrudomide — Chronic Lymphocytic Leukemia Phase 1
- zelebrudomide — Marginal Zone Lymphoma Phase 1
- zelebrudomide — Waldenström's Macroglobulinemia Phase 1
- bexobrutideg — Multiple Sclerosis Phase 2
- bexobrutideg — Chronic Spontaneous Urticaria Phase 2
- civorebrutinib — Primary Membranous Nephropathy Phase 2
- civorebrutinib — Focal Segmental Glomerulosclerosis Preclinical
- civorebrutinib — Minimal Change Disease Preclinical
- orelabrutinib — Primary Progressive Multiple Sclerosis Phase 3
- orelabrutinib — Secondary Progressive Multiple Sclerosis Phase 3
